Study Details

Open

Myelodysplastic Syndrome or Acute Myeloid Leukemia study

This is a research study for people diagnosed MDS or AML. The purpose of this study is to see if the study drug SL-172154, works better alone or in combination azacitidine or with azacitidine and venetoclax.

Age & Gender

18 years ~ 75 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

North Carolina (Statewide)

What will be asked of you

If you decide to take part you will receive SL-172154 as an infusion into a vein once a week. The infusion will take about 60-120 minutes. If receiving azacitidine, it will be given to you as an infusion in your vein and will take about 10-40 minutes or as an injection under the skin once daily for 7 days every 28 days. If you receive venetoclax, it will be administered orally every day. At each visit you will be asked questions about your health and any other medications you're taking. Blood draws for routine tests should be expected at every onsite visit. Throughout the study, a test will be performed that measures the amount of oxygen in your blood. We will collect marrow aspirate and blood throughout this study for your safety.

Incentives

study medication, gas reimbursement, as applicable, and Lodging Reimbursement as applicable.

In-person visits:
21+

Total length of participation:
8+ months

Looking for Specific Volunteers

Able to participate:

You are diagnosed with AML or MDS
You have good kidney and liver function
You are between the ages of 18 and 75 years old.

Not eligible if:

You have been diagnosed with any of the following, Atypical chronic myeloid leukemia (CML), Juvenile myelomonocytic leukemia (JMML), chronic myelomonocytic leukemia (CMML), and unclassifiable MDS/MPN.
You have been diagnosed with stomach or intestinal disease.
You have heart disease
You have had previous treatment with certain medications.
You are actively bleeding or have a bleeding disorder.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Joshua Zeidner
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Leukemia)

IRB Number

22-1852

ClinicalTrials.gov

NCT05275439